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1Sharon Stancliff, MD, Kimberly 
Sue, MD, PhD, and Bruce 
Trigg, MD, have reviewed the 
information presented in this 
document for medical accuracy. 
However, this information should 
not be considered medical 
advice for health care providers, 
counselors, nurses or other 
professionals directly involved in 
the clinical care for women who 
use drugs, and is not a substitute 
for individualized patient or client 
care and treatment decisions. 
Please consult a medical 
professional for such advice. 
Unfortunately, pregnant women who use drugs face 
highly stigmatizing and inaccurate perceptions from both 
health care providers and the public at large, negatively 
impacting the quality of their care and supportive services. 
This publication seeks to move beyond the myths and 
anxieties about drug use during pregnancy to recommend 
simple approaches to benefit and protect the health of both 
pregnant women and newborns. These lessons are being 
learned across the globe: a growing number of countries, 
including Australia, Canada, Romania, Ukraine, and the 
United Kingdom, and institutions and agencies such as the 
World Health Organization have updated their protocols 
to reflect the understanding that drug use in pregnancy 
is not a “moral failing” and need not necessarily lead to 
bad health outcomes.1 Common to effective approaches 
is a commitment to prioritizing access to supportive, 
nonjudgmental care respectful of women’s rights and choices 
over interventions that emphasize control and punishment, 
or deny women an opportunity to participate in decisions 
affecting their lives and that of their families.   
Based on review of national and international practice 
and evidence, the principles described here can help those 
seeking to improve policies and practices that affect pregnant 
women who use drugs. 
Author’s Note 
This publication is 
largely based on the 
research and practice of 
health care for pregnant 
cisgender women who 
use drugs. However, 
there are experiences 
and lessons learned here 
that are applicable to all 
pregnant people.
Drug use in pregnancy can lead to 
serious health risks for both the 
mother and the fetus, including 
HIV infection and fatal overdose. 
At the same time, drug use 
during pregnancy need not lead 
to any negative outcomes, or to 
outcomes significantly different 
from those experienced by non 
drug-using women.
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4Combat Misinformation  
with Facts
“It is impossible 
for babies to be 
born addicted. 
This language is 
stigmatizing and 
incorrect. Please 
challenge anyone 
who uses this 
terminology.”
Loretta Finnegan, MD6
Few behaviors by women are as stigmatized as using drugs 
while pregnant. Across cultures and religions, women who 
use drugs and become pregnant are portrayed as unfit 
or irresponsible mothers. Media reporting on this issue, 
too often leans toward the sensational. Images of babies 
experiencing opioid withdrawal symptoms emphasize  
their suffering and suggest, inaccurately, that they will 
experience long-term harm. In the United States, during the 
1980s and 1990s, media reports of “crack babies” implied 
that children born to mothers who used crack cocaine were 
permanently damaged. 
Research shows that media claims of developmental harm 
to the fetus from prenatal drug exposure—whether legal and 
illegal—are greatly exaggerated. In contrast, environmental 
5factors such as social isolation, poverty, food insecurity, and 
lack of access to quality health care can have a greater impact 
on the health of a baby than prenatal exposure to drugs.2
In a systematic review of 200 studies on children exposed 
to opioids in utero, findings indicated “no significant 
impairments in cognitive, psychomotor or observed 
behavioral outcomes for chronic intrauterine exposed 
infants and preschool children.”3 Exposure to opioids in 
utero can have short-term health implications after birth—
primarily withdrawal symptoms, also called “neonatal 
abstinence syndrome" or “neonatal opioid withdrawal.” 
These withdrawal symptoms are also associated with 
medically prescribed treatment for opioid dependence 
during pregnancy, such as methadone and buprenorphine.4 
Contrary to much media coverage, neonatal abstinence 
syndrome is a short-term and easily treatable condition that 
does not have a lasting impact.
Similarly, claims about so-called “crack babies” suffering 
from long-term developmental delay lacked evidence 
and were proven to be largely driven by racist stereotypes 
rather than facts. The brain-damaged “crack baby” was 
a myth: A recent systematic review following cocaine 
prenatal exposure found “no consistent negative association 
between prenatal cocaine exposure and physical growth, 
developmental test scores, or receptive or expressive 
language.”5
It is also medically inaccurate to report any prenatally drug-
exposed infant as “born addicted.” Addiction is defined as a 
set of behaviors that includes seeking opioids or other drugs 
despite negative social consequences, a description clearly 
inapplicable to infants. By disregarding the distinction 
between dependence and addiction, and ignoring the short-
term nature of neonatal withdrawal, media hype perpetuates 
stigma, misinformation and punitive measures—such 
as mandatory drug testing and removal of children from 
parental care. Stigmatizing and punitive responses can 
discourage women from seeking evidence-based treatment 
and support. Advocates can help steer public conversation 
toward a discussion that is informed by the evidence and 
moves beyond scaremongering and stigma. 
6“Drug enforcement 
policies that deter 
women from 
seeking prenatal 
care are contrary 
to the welfare of 
the mother and 
fetus. Incarceration 
and the threat 
of incarceration 
have proved to 
be ineffective 
in reducing the 
incidence of alcohol 
or drug abuse.”
Do Not Criminalize Pregnant 
Women Who Use Drugs
Committee opinion from  
The American College of 
Obstetrics and Gynecologists15
It is critical that pregnant women not face criminal charges, 
incarceration, and/or removal of their babies simply for the 
fact of drug use. 
In the United States, for example, the state of Tennessee 
made drug use in pregnancy a crime of “fetal assault,” 
resulting in incarceration of some pregnant women and 
new mothers for up to 15 years. The law, widely criticized by 
health care professionals, expired in 2016.7 Since 1973, at 
least 45 states in the United States have sought prosecution 
for prenatal drug use under a wide variety of charges 
such as child endangerment, abuse, or neglect, and even 
manslaughter and second-degree murder if a pregnancy 
ends in a miscarriage.8 Ostensibly aimed at protecting the 
fetus, in reality these charges may endanger newborns and 
mothers alike, leading drug using women to avoid prenatal 
care and drug dependence treatment—two things that may 
actually have the most positive impact on the health of the 
baby and the mother.9
The claim that criminalization or other sanctions such as 
removal of parental rights can be an effective way to deter 
drug use is unsupported by evidence. Fear of arrest or loss 
of parental rights, however, has been shown to weaken 
the relationship between pregnant women and health care 
providers, especially when the providers are legally obligated 
to report drug use to law enforcement or child protection 
agencies.10 In the United States, states with laws that 
permit child abuse charges for drug use in pregnancy have 
fewer women enrolled in evidence-based drug treatment 
than states that do not have such laws.11 Furthermore, 
criminalizing pregnant women fails to address common 
social factors that are often associated with drug use such as 
poverty, intimate partner violence, or previous trauma. In 
Norway, pregnant women who continue to use drugs can be 
forcibly detained in a residential facility, without consent, 
for the duration of their pregnancy12 while other services 
available to people who inject drugs, such as access to a 
medically supervised site to inject drugs, are unavailable to 
pregnant women. 
There are many major public health organizations and 
national health authorities that oppose using criminal 
sanctions to address drug use during pregnancy. World 
7Health Organization guidelines list “risk of incarceration/
loss of infant in punitive systems” among harms to be 
avoided.13 Similarly, the American College of Obstetricians 
and Gynecologists issued an explicit statement against 
applying punitive drug enforcement policies to pregnant 
women, and called instead for appropriate public health 
interventions based on science and evidence.14
8“The drug user 
registry [in Russia] 
could be sufficient 
grounds to deprive 
or limit a person’s 
parental rights. This 
has had an especially 
profound negative 
effect on pregnant 
women who use 
drugs, who avoid 
contact with the 
health care system 
for fear of losing 
their parental rights, 
including child 
custody.”
Respect Confidentiality and 
Ensure Informed Consent 
Mikhail Golichenko and Sandra 
Ka Hon Chu, researchers and 
advocates for the Canadian  
HIV/AIDS Legal Network23
Honest discussion between health providers and pregnant 
women about their drug use can increase their chances to 
receive information, care, and support that will benefit their 
health and that of their newborns. Unfortunately, disclosure 
of drug use also makes women vulnerable to discrimination 
and increased scrutiny by law enforcement or child 
protection agencies, a risk particularly high for minority  
and poor women. In Georgia, Russia, and Ukraine, people 
who use drugs are required to register as a “drug user” when 
they seek drug treatment through the public system, which 
can lead to termination of parental rights.16 In Ukraine, 
despite HIV privacy laws, women report having their HIV 
and drug use status disclosed by health providers, leading 
to denial of health services, and humiliating and abusive 
treatment by medical staff.17 In the United States, a Florida 
study showed that while white and black women had equal 
rates of drug use in pregnancy, black women were 10 times 
more likely to be reported to government health authorities 
for their drug use.18 Similarly, drug testing without informed 
consent is often applied selectively, disproportionately 
impacting poor women and women of color using 
government-funded health care.19
Even if women are informed about drug tests and their 
potential consequences, they do not always have the  
power to refuse. 
The World Health Organization recognizes the right to 
confidentiality and informed consent as the “fundamental 
right of all health care users.”20 International and national 
experts agree that informed consent is key to fostering the 
climate of trust, respect, and collaboration between the 
health provider and pregnant women,21,22 and that advocates 
and health providers have a role to play in advancing policies 
and practices that respect women’s autonomy and dignity. 
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Ensure Access to Harm Reduction 
Services 
Implementing a harm reduction approach for pregnant 
women who use drugs is based on an understanding that 
drug use is just one of the factors that shape a pregnancy, and 
that improvements beside abstinence from all criminalized 
drug use can have a positive effect on the woman’s health 
and that of her fetus or newborn. 
While abstaining from criminalized drugs is the best way 
to protect oneself and a fetus from drug-related harm, 
health improvement does not require cessation of drug use. 
Women can reduce the amount or frequency of drug use, 
learn how to use drugs more safely to prevent HIV, hepatitis 
C or overdose,24 and take other steps to protect their health. 
A harm reduction approach for service providers means 
being willing to discuss goals other than abstinence, such as 
improving housing, nutrition, regularity of prenatal care, and 
safety, all of which are crucial for a healthy pregnancy.25 This 
is both pragmatic and effective. Denying prenatal and other 
health services to a woman who is pregnant and using drugs 
will increase the harm, not reduce it.26
Many women who use drugs come in contact with harm 
reduction services in their community before they try to 
access mainstream health care. Services, such as needle 
and syringe programs, or street-based outreach nursing, 
can provide a friendly, nonjudgmental and supportive 
environment, where women might be more comfortable to 
disclose their drug use, receive counseling, and connect to 
friendly prenatal care and drug treatment providers.27 Harm 
reduction programs can also provide supports, including 
peer support, to help break social isolation that some women 
who use drugs face, particularly women who have been 
recently incarcerated or migrant women. 
Despite being “low threshold,” in some communities 
harm reduction programs might be difficult for women 
to access. Cuts in funding have made harm reduction 
services less available in many middle-income countries,28 
particularly for women. In many contexts, existing services 
lack tailored, women-specific interventions.29 This can 
create unsafe or unwelcoming environments for women, 
particularly in societies with traditional gender roles, like 
Georgia, where only 2 percent of people engaging in harm 
reduction are women, but where women using drugs are 
11
Harm reduction programs can take a number  
of steps to meet the needs of pregnant women.  
Some examples include: 
often “second on the needle” and so at greater risk of 
blood-borne infection.30,31 Additionally, pregnant women 
may avoid services because they face especially severe 
stigma and judgment from other service users. Few harm 
reduction programs offer pregnancy tests, childcare, or cover 
transportation costs,32 while women who use drugs usually 
bear the bulk of caretaking responsibilities and are more 
likely to live in poverty.33
Programs might also explicitly prevent pregnant women 
from access. In Denmark, where a full range of harm 
reduction interventions are available to those who need 
them, pregnant women are the only group who are expressly 
excluded from supervised drug consumption facilities and 
heroin treatment programs despite evidence that these 
interventions are effective in preventing overdose and 
reducing other adverse consequences of injection.34 By 
contrast, similar programs in Vancouver, Canada, do not 
deny access to pregnant women, recognizing them as clients 
who stand most to benefit from these interventions.35
Increasing availability and accessibility of harm reduction 
services for women can increase opportunities for engaging 
pregnant women who use drugs in care and provide a point 
of entry for prenatal care and treatment.
• Ensure access of pregnant women to all available evidence-based harm 
reduction services by creating a safe and welcoming environment.  
This might include women-only safe spaces, mobile services that can  
meet women where they are, and having more women on staff.
• Repeal regulations barring pregnant women from use of medically 
supervised injection facilities.
• Offer free pregnancy tests, baby supplies, and childcare.
• Offer empowerment and education to address intimate partner violence  
and provide access to legal aid, including on issues of parental rights 
and custody.
• Foster links to non-judgmental pre- and postnatal health care, counseling 
services, employment, education, housing, or other resources within  
the community. 
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Facilitate Access to Methadone 
and Buprenorphine 
Anonymous participant in 
a buprenorphine consumer 
listening session42
Detoxification from all opioids carries significant health 
risks for pregnant women who are dependent on opioids,36 
yet misinformed providers often persuade women to cease 
all opioid use during pregnancy. In some cases, the provider 
may reprimand or otherwise seek to punish a woman if she 
refuses to follow the provider’s enforced abstinence-only 
treatment. Pregnancy is the time when many women who 
use drugs have the greatest chance to benefit from access to 
supportive care, including engaging in opioid dependence 
treatment with the medications methadone or buprenorphine. 
Many international guidelines such as those from the World 
Health Organization, UNAIDS, and the UN Office on Drugs 
and Crime, recommend methadone or buprenorphine as the 
most effective and safe treatment options for people with 
problematic opioid dependencies and these medicines are 
approved for women using heroin or other opioids during 
and after pregnancy.37 As with any medications, methadone 
and buprenorphine are associated with some risks; however, 
research shows that the benefits of these medicines far 
outweigh the associated risks in pregnancy, and that their use 
is safer than attempting cessation of all opioid use.38 Instead of 
a pregnant woman becoming sick with withdrawal symptoms 
and then engaging in risky behaviors to obtain unregulated 
drugs, use of legally prescribed methadone or buprenorphine 
can provide physical relief and stability. This stability protects 
the health of the mother and her fetus as well as opens up 
opportunities to connect women to care and supportive 
services. Methadone or buprenorphine can be combined with 
social work and other comprehensive care (i.e., stable housing, 
nutrition education, counseling, additional health care).39  As 
previously noted, while methadone and buprenorphine can 
cause temporary neonatal abstinence syndrome symptoms 
for the baby after birth, these symptoms are treatable and 
nonlife-threatening.40 It is recommended that methadone or 
buprenorphine be continued during the postpartum period 
to reduce the risk of returning to problematic opioid use and 
experiencing a potential overdose.41
It is important that pregnant women are informed of all 
available treatment options in their communities. Ultimately, 
a woman’s own decision on whether to use any of the 
treatment options must be respected and supported.
“I’ve had both 
of my babies 
while taking 
buprenorphine 
and they are  
both happy  
and healthy.”
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Ensure Access to Adequate Pain 
Relief during Labor
“I was never offered 
pain medications 
during any of my 
pregnancies. I even 
broke my arm while 
on buprenorphine 
and the doctor 
assumed I was just 
‘drug seeking.’”
Anonymous participant 
at a New York City harm 
reduction program49
Many women require access to adequate pain management 
in childbirth, and women who use drugs are no exception. 
Rather than being offered supportive care during labor and 
delivery—an incredibly stressful time for any woman—
women who use drugs may receive substandard medical 
care. Women who use drugs might have barriers in accessing 
pain relief during and after labor for a number of reasons 
including the common discriminatory suspicion that people 
who use drugs are just “seeking drugs.” For women who are 
opioid dependent, anticipated anxieties can be associated 
with problematic intravenous access and inadequate 
pain management.43 Additionally, there is evidence that 
stigmatizing beliefs and practices among health care 
providers often yield negative health outcomes for patients 
with known drug use.44
Existing research shows that pain can be successfully 
managed in women who are dependent on opioids during 
labor and delivery.45 There is no evidence that exposure to 
pain-relieving medications during childbirth increases risks 
of problematic drug use after delivery in pregnant women 
who had used drugs and stopped prior to pregnancy or 
delivery. Without proper pain management, intensive pain 
during labor and delivery can lead to long-term physical, 
psychological, and emotional impacts for the mother.46 
For pregnant women who are opioid dependent, denial 
of or inappropriate pain management can lead to return 
to criminalized drug use.47 Discussing pain management 
options with pregnant women early in pregnancy can be one 
way to foster a relationship of trust and support between 
the prenatal care provider and the woman to strengthen the 
woman’s motivation to stay engaged in care.48
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Support Women through  
Birth and After 
“As soon as a woman 
who is using [drugs] 
gets pregnant, 
society often forgets 
about her and 
focuses on keeping 
the baby safe, but we 
must remember and 
understand that the 
mother and baby are 
a dyad and must be 
treated as a unit.”
Outreach nurse  
in Vancouver’s  
Lower Eastside54
After a woman who uses drugs gives birth, some countries 
immediately separate the mother and baby in order to place 
the baby in an intensive medical care unit for observation. 
Immediate separation can also occur in countries in which 
a woman faces arrest or detention for drug use during her 
pregnancy. Childbirth, a time that can be filled with joy and 
love, suddenly becomes incredibly stressful for mothers 
who may suffer feelings of deep shame and sadness from 
the sudden, enforced separation. Again, harsh judgments 
from care providers and exaggerated misconceptions about 
drug use during pregnancy make this worse. Well-meaning 
providers often believe they are “protecting” the baby by this 
separation, when in fact, mounting research recommends 
the importance of supportive bonding after birth, including 
for mothers who used drugs. 
Skin-to-skin physical contact or “rooming-in” after birth 
has many benefits for mothers and their newborns.50 For a 
woman who used drugs during her pregnancy, encouraging 
skin-to-skin contact, including aiding in breastfeeding, 
has the potential to improve the mother’s motivation to 
decrease problematic drug use and seek treatment.51 In 
addition, allowing opportunities for physical bonding after 
birth can erode certain misconceptions about the mother’s 
caregiver capabilities and build trust with her providers. 
In a systematic review of the best practices for babies 
exposed to opioids during pregnancy, recommendations 
included maintaining physical contact in a low stimulation 
environment (e.g., dim lighting) through breastfeeding, 
swaddling, massage, and cuddling.52 Research shows that 
immediate, forced separation could cause further emotional 
trauma for the vulnerable mother and even increase 
symptoms of neonatal abstinence syndrome in babies who 
are opiate dependent.53
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Connect Women to Domestic  
Violence Services When Necessary 
Women who use drugs often experience physical, sexual, 
and emotional violence and abuse. While violence from 
an intimate partner is common, women who use drugs 
can also experience violence from sex work clients, law 
enforcement officers, suppliers of unregulated drugs, 
family members, or peers. In many cases, women depend 
on their abusive partners for housing, drugs or income and 
may risk becoming homeless if they leave. Women who 
experience violence are at increased risk of being a victim 
of homicide, preterm labor, miscarriage, and other obstetric 
complications.55 Intimate partner violence can also hinder 
the negotiation of condom use and increase risk of HIV. 
Research suggests that women with a history of experiencing 
violence are more likely to continue drug use as a way to self-
medicate and cope with the trauma.56
Because drug use is both incredibly stigmatized and 
criminalized in many countries, there are significant barriers 
for pregnant women to seek support when facing violence. 
Many antiviolence programs or shelters do not to admit 
women who are active drug users, claiming they do not  
have the capacity to help, while harm reduction services  
rarely address issues of violence explicitly.57 Advocacy  
to make domestic violence shelters open to pregnant  
women who use drugs is crucial to improving their safety. 
Fostering connections and coordination among antiviolence 
services and harm reduction programs has the potential  
to reduce significant barriers to timely access to health  
care and other services. 
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Make It Easier to Navigate Health 
and Social Services
A pregnant woman who uses drugs may need a variety 
of services offered by different providers, including an 
obstetrician, midwife, social worker, drug treatment 
provider, and many others. Globally, there are few health 
and social services systems that provide integrated and 
coordinated care for pregnant women who use drugs. In 
most cases, the burden of navigating a complex system, 
where many providers are located in different parts of town 
or require different documentation, is on women who are 
already in stressful situations. This burden only increases if a 
woman also has to address legal issues or challenges related 
to child custody.
A comprehensive, coordinated approach is essential to 
provide optimal care for pregnant women who use drugs. 
One way to strengthen coordination is to involve managers 
trained in harm reduction who can liaise with the many 
different types of services. Evidence shows that community-
based case management services for women who use drugs 
can significantly improve women’s ability to stay engaged in 
supportive care and treatment.58
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Introduce National Guidelines 
Based on Evidence and Respect 
for Human Rights
National clinical guidelines, based on rigorously researched 
evidence, human rights standards, and respect for 
confidentiality, are an important way to ensure that pregnant 
women who use drugs can access the care they need without 
stigma or discrimination. 
Guidelines are a set of practical recommendations, 
frequently issued by the national health authority, for all 
health and social service providers who are involved in caring 
for pregnant women who use drugs and their children. The 
guidelines are usually developed by a collective of experts 
and practitioners, who review existing clinical evidence and 
best practices, and recommend each intervention based on 
the strength of this evidence. The guidelines also set out key 
goals in providing care, designate responsible providers, and 
describe underlying principles and values. Once adopted, 
the guidelines serve as standards of care against which 
providers can be held accountable for violations or for failing 
to provide the expected quality of care. 
In 2014, when the World Health Organization introduced the 
first global evidence-based recommendations on managing 
pregnancy and drug use, only a handful of countries had 
national guidelines covering these issues.59 Today, countries 
including Australia and Canada have also articulated 
guidelines, though many countries have yet to do so. 
The existing international and national guidelines share 
several important points:
• They aim to “safeguard against stigma and discrimination” 
and recognize that women should have a voice and 
autonomy in decisions about treatment options. (World 
Health Organization)60
• They prioritize establishing a “trusting and empathetic 
relationship in which the women will feel encouraged to 
continue pregnancy care.” (Australia)61
• They emphasize the importance of informed consent, 
particularly for interventions, such as drug testing, that 
might negatively impact women’s legal rights. (Canada)62
• They integrate harm reduction approaches for pregnant 
women, despite continued drug use. (UNODC)63
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• They prioritize evidence-based information over moralistic 
attitudes. (European Monitoring Centre for Drugs and 
Drug Addiction)64
• They recognize the mother and infant as a dyad to 
“optimize the outcomes for the mother–infant dyad as a 
whole.” (United States)65
While introducing a set of recommendations at the national 
level is the first step toward improving care available to 
pregnant women who use drugs, it is not the last one.  
Civil society has a role to play in ensuring that the guidelines 
actually work: that the providers are trained and have 
resources to implement them; that violations are monitored 
and reported; and that recommendations are regularly 
reviewed and updated based on the latest evidence. 
20
Selected Resources for Advocates
View the electronic version of this report at  
osf.to/expectingbetter for hyperlink access  
to these resources.
Women Who Use Drugs, Harm Reduction and 
HIV66
An issue brief developed by advocates and women 
with lived experience of drug use. It highlights several 
gender-specific challenges in harm reduction and offers 
an overview of recommendations for national and 
international programmatic and policy interventions. 
Women Speak Out: Understanding Women Who 
Inject Drugs in Indonesia67
Findings from a participatory research study among 
women who use drugs in Indonesia, including 
programmatic and policy recommendations. 
Pregnant Women and Substance Use: Overview of 
Research & Policy in the United States68
A United States-based set of policy recommendations 
focusing on the health and human rights of pregnant 
women who use drugs that highlights the history and 
consequences of stigma and racial discrimination. 
 
Harm Reduction and Pregnancy: Community-
based Approaches to Prenatal Substance Use in 
Western Canada69
A booklet that defines several harm reduction approaches for 
the population of pregnant women and offers examples of 
several best practice programs in Western Canada.
Making Harm Reduction Work for Women70
A summary of findings from a needs assessment and 
recommendations for implementing gender-responsive 
harm reduction for women in Ukraine.
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By Women, For Women: New Approaches to 
Harm Reduction in Russia71
A summary of findings from a needs assessment and 
recommendations for implementing gender-responsive 
harm reduction for women in Russia.
Intimate Partner Violence During Pregnancy72
Global information fact sheet on the prevalence and 
consequences of intimate partner violence during 
pregnancy.
Women, Drug Policies, and Incarceration73
A guide that urges policymakers in Latin America to take 
into consideration the multiple factors women charged 
with drug-related crimes have, for example, pregnancy 
and caring for dependents.
National Advocates for Pregnant Women74
advocatesforpregnantwomen.org
A United States-based nonprofit offering legal advocacy 
and public education on the rights of pregnant women 
with a particular focus on women impacted by punitive 
“war on drugs” policies.
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